05:25 AM EST, 11/09/2026 (MT Newswires) -- Thalia Therapeutics (THAT.L) unit Sanmirna Therapeutics signed a clinical trial agreement for the ongoing phase 1 study of miRisten, a potential treatment for relapsed or refractory acute myeloid leukemia. The UK-listed biotechnology company said Monday that the agreement with US-based City of Hope will allow the parties access to information related to the dose escalation trial, including results and budget confirmation. City of Hope discovered miRisten and licensed the intellectual property rights to Sanmirna. Interim results are expected to be released in the fourth quarter of 2026, with topline data slated for the first half of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.